Catheter Precision to Attend the International Symposium on Catheter Ablation Techniques
Catheter Precision (NYSE/American:VTAK) announced its participation in the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16-18 in Paris, France. ISCAT is a biannual European meeting focusing on new and emerging catheter ablation technologies, techniques, and study data for atrial and ventricular arrhythmias.
CEO David Jenkins emphasized the importance of attending such meetings as part of their sales strategy, stating that it provides an opportunity to meet physicians, showcase technologies, and generate new sales leads. At ISCAT, Catheter Precision plans to demonstrate their VIVO technology and highlight recent clinical data presented at the European Society of Cardiology meeting in September, which demonstrates VIVO's value and accuracy.
Catheter Precision (NYSE/American:VTAK) ha annunciato la sua partecipazione al 15° Simposio Internazionale sulle Tecniche di Ablazione con Catetere (ISCAT), che si svolgerà dal 16 al 18 ottobre a Parigi, Francia. L'ISCAT è un incontro europeo biennale che si concentra sulle nuove e emergenti tecnologie di ablazione con catetere, tecniche e dati di studio per le aritmie atriali e ventricolari.
Il CEO David Jenkins ha sottolineato l'importanza di partecipare a tali incontri come parte della loro strategia di vendita, affermando che offre l'opportunità di incontrare medici, presentare tecnologie e generare nuovi contatti di vendita. All'ISCAT, Catheter Precision prevede di dimostrare la propria tecnologia VIVO e mettere in evidenza i recenti dati clinici presentati durante il meeting della Società Europea di Cardiologia a settembre, che dimostrano il valore e l'accuratezza di VIVO.
Catheter Precision (NYSE/American:VTAK) anunció su participación en el 15º Simposio Internacional sobre Técnicas de Ablación con Catéter (ISCAT), que se llevará a cabo del 16 al 18 de octubre en París, Francia. ISCAT es una reunión europea bienal que se centra en las nuevas y emergentes tecnologías de ablación con catéter, técnicas y datos de estudio para las arritmias auriculares y ventriculares.
El CEO David Jenkins enfatizó la importancia de asistir a tales reuniones como parte de su estrategia de ventas, afirmando que proporciona una oportunidad para conocer a médicos, mostrar tecnologías y generar nuevos prospectos de ventas. En ISCAT, Catheter Precision planea demostrar su tecnología VIVO y resaltar los recientes datos clínicos presentados en el congreso de la Sociedad Europea de Cardiología en septiembre, que demuestran el valor y la precisión de VIVO.
Catheter Precision (NYSE/American:VTAK)는 프랑스 파리에서 10월 16일부터 18일까지 열리는 제15회 국제 카테터 절제기술 심포지엄(ISCAT)에 참여한다고 발표했습니다. ISCAT는 심방 및 심실 부정맥을 위한 새로운 및 출현 중인 카테터 절제 기술, 기법 및 연구 데이터를 중심으로 하는 유럽의 격년 회의입니다.
CEO David Jenkins는 이러한 회의에 참석하는 것이 판매 전략의 일환으로서 중요하다고 강조하며, 이는 의사들과 만나고, 기술을 선보이며, 새로운 판매 기회를 창출할 수 있는 기회를 제공한다고 말했습니다. ISCAT에서 Catheter Precision은 자신의 VIVO 기술를 시연하고, 9월에 유럽심장학회에서 발표된 최근 임상 데이터를 강조할 계획이며, 이는 VIVO의 가치와 정확성을 보여줍니다.
Catheter Precision (NYSE/American:VTAK) a annoncé sa participation au 15e Symposium International sur les Techniques d'Ablation par Cathéter (ISCAT), qui se déroulera du 16 au 18 octobre à Paris, France. L'ISCAT est une réunion européenne qui se tient tous les deux ans, axée sur les nouvelles et émergentes technologies d'ablation par cathéter, techniques et données d'études pour les arythmies atriales et ventriculaires.
Le PDG David Jenkins a souligné l'importance d'assister à de telles réunions dans le cadre de leur stratégie de vente, affirmant que cela offre l'occasion de rencontrer des médecins, de présenter des technologies et de générer de nouveaux contacts commerciaux. Lors de l'ISCAT, Catheter Precision prévoit de démontrer sa technologie VIVO et de mettre en avant les données cliniques récentes présentées lors de la réunion de la Société Européenne de Cardiologie en septembre, qui démontrent la valeur et la précision de VIVO.
Catheter Precision (NYSE/American:VTAK) hat seine Teilnahme am 15. Internationalen Symposium über Katheterablationstechniken (ISCAT) angekündigt, das vom 16. bis 18. Oktober in Paris, Frankreich, stattfinden wird. ISCAT ist ein biennales europäisches Treffen, das sich auf neue und aufkommende Katheterablationstechnologien, -techniken und Studienergebnisse für atriale und ventrikuläre Arrhythmien konzentriert.
CEO David Jenkins betonte die Bedeutung der Teilnahme an solchen Treffen im Rahmen ihrer Verkaufsstrategie und erklärte, dass dies eine Gelegenheit bietet, Ärzte zu treffen, Technologien zu präsentieren und neue Verkaufsleads zu generieren. Auf der ISCAT plant Catheter Precision, seine VIVO-Technologie vorzuführen und die kürzlich auf dem Kongress der Europäischen Gesellschaft für Kardiologie im September präsentierten klinischen Daten hervorzuheben, die den Wert und die Genauigkeit von VIVO belegen.
- None.
- None.
FORT MILL, SC / ACCESSWIRE / October 15, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16 - 18 in Paris, France.
ISCAT is a biannual European meeting that focuses on new and emerging catheter ablation technologies, techniques, and study data for both atrial and ventricular arrhythmias.
"Attending meetings is a crucial part of our sales strategy," said David Jenkins, CEO of Catheter Precision. "Meetings allow us the chance to meet with physicians in a dedicated, focused setting and showcase our technologies while generating new sales leads. In this case, we will demonstrate VIVO and highlight our newest clinical data, demonstrating the value and accuracy of VIVO, that was presented in September at the European Society of Cardiology meeting."
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision, Inc.
View the original press release on accesswire.com
FAQ
When and where is Catheter Precision (VTAK) attending the International Symposium on Catheter Ablation Techniques?
What will Catheter Precision (VTAK) showcase at ISCAT 2024?
Why is Catheter Precision (VTAK) attending ISCAT according to CEO David Jenkins?
What is the focus of the International Symposium on Catheter Ablation Techniques that Catheter Precision (VTAK) is attending?
